(1-methylethylidene)di-4,1-phenylenetetraphenyl diphosphate

Repeated dose toxicity: oral

Administrative data

Endpoint:

short-term repeated dose toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: Guideline study with GLP

Cross-reference

Cross-reference 1

Reason / purpose for cross-reference:

reference to same study

Cross-reference 2

Reason / purpose for cross-reference:

reference to other study

Data source

Reference

Reference 1

Reference Type:

review article or handbook

Title:

Unnamed

Year:

2000

Reference 2

Reference Type:

other company data

Title:

Unnamed

Year:

1997

Reference 3

Reference Type:

other: monograph provided by ECHA

Title:

Endpoint record:Repeated toxicity

Author:

ECHA

Year:

2010

Bibliographic source:

Document from ECHA

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))

Principles of method if other than guideline:

There is no need to add in this field.

GLP compliance:

yes

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

5945-33-5

EC Number:

611-829-8

Cas Number:

5945-33-5

IUPAC Name:

5945-33-5

Constituent 2

Reference substance name:

-

EC Number:

425-220-8

EC Name:

-

Cas Number:

5945-33-5

Molecular formula:

C39H34O8P2

IUPAC Name:

4-(2-{4-[(diphenoxyphosphoryl)oxy]phenyl}propan-2-yl)phenyl diphenyl phosphate; 4-{2-[4-({[4-(2-{4-[(diphenoxyphosphoryl)oxy]phenyl}propan-2-yl)phenoxy](phenoxy)phosphoryl}oxy)phenyl]propan-2-yl}phenyl diphenyl phosphate

Details on test material:

75 - 95% (typical 88%, verified by UV/visible spectrum, Infrared (IR) spectrum, Nuclear Magnetic Resonance (NMR), and Mass spectrum.)

Test animals

Species:

rat

Strain:

Sprague-Dawley

Sex:

male/female

Details on test animals or test system and environmental conditions:

Rat/Sprague Dawley Crl:CD

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

polyethylene glycol

Remarks:

400

Details on oral exposure:

0, 15, 150, 1000 mg/kg/day for 28 consecutive days followed by a 14 day treatment free (recovery) period

Analytical verification of doses or concentrations:

not specified

Details on analytical verification of doses or concentrations:

no data

Duration of treatment / exposure:

28 consecutive days followed by a 14 day treatment free (recovery) period.

Frequency of treatment:

0, 15, 150, 1000 mg/kg/day for 28 consecutive days

Doses / concentrations

Remarks:

Doses / Concentrations:
0, 15, 150, 1000 mg/kg/day
Basis:
no data

No. of animals per sex per dose:

5/sex/group; 3 test groups, 1 control group, 2 recovery groups (high dose and vehicle)

Control animals:

yes

Details on study design:

Nothing to add in this field.

Positive control:

no data

Examinations

Observations and examinations performed and frequency:

Clinical Observation
YES
Clinical Chemistry/Haematology: yes
Blood chemistry:ALT,AST
Urinalysis:urine volumes, urine specific gravity

Sacrifice and pathology:

GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes

Other examinations:

Nothing to add in this field.

Statistics:

no data

Results and discussion

Results of examinations

Clinical signs:

no effects observed

Mortality:

no mortality observed

Body weight and weight changes:

no effects observed

Food consumption and compound intake (if feeding study):

no effects observed

Food efficiency:

not specified

Water consumption and compound intake (if drinking water study):

not specified

Ophthalmological findings:

no effects observed

Haematological findings:

no effects observed

Clinical biochemistry findings:

no effects observed

Urinalysis findings:

no effects observed

Behaviour (functional findings):

not specified

Organ weight findings including organ / body weight ratios:

no effects observed

Gross pathological findings:

no effects observed

Histopathological findings: non-neoplastic:

no effects observed

Histopathological findings: neoplastic:

no effects observed

Details on results:

Clinical observations
There were no deaths during the study period.One control male developed a scab in the dorso-cervical region from day 7 to day 16, which
was attributed to injury. A female in the 150 mg/kg/day group had clinical signs including hunched posture and pilo-erection but these were not considered to be treatment-related since these effects were not detected at 1 000 mg/kg/day.
Clinical Chemistry/Haematology
Blood chemistry
A statistically significant reduction or increase in alanine amino transferase (ALT) was detected in males at 15 or 150 mg/kg/day, respectively, compared with controls. In the absence of adverse effects at the high dose level of 1000 mg/kg/day, and that the values were within the normal range for this strain of rat, these findings were not considered to be treatment-related.
Males treated with 15 or 1000 mg/kg/day also showed a statistically significant reduction in aspartate amino transferase (AST). As these levels were also in the normal range, they were not considered to be toxicologically important.

Urinalysis
Recovery 1000 mg/kg/day females showed a statistically significant reduction in urine volumes and increase in urine specific gravity compared with controls. Since no such changes were detected following 28 days of treatment, they were not considered to be toxicologically important.

Organ weights
The statistically significant increases in absolute ovary weight detected for females treated with 1000 or 150 mg/kg/day and the reduction in absolute liver weight detected in recovery 1000 mg/kg/day females were not reflected in the relative weights. These effects were therefore not considered to be treatment-related.

Necropsy
The incidental findings recorded for one recovery control male and one non-recovery control female, identified as hydronephrosis of the right kidney or dark patches on all lobes of the lung, respectively, showed no dose-response relationship and were consistent with normally expected low findings for this strain of rat. These effects were therefore not considered to be treatment-related.

Histopathology
The reported microscopic cardiac, hepatic and renal findings were consistent with normally expected low findings for this strain of rat. There were also microscopic changes in the lung of one non-recovery female, associated with macroscopic findings and more probably representing an artefactual, procedure-related lesion. These effects were therefore not considered to be treatment-related.

Effect levels

Dose descriptor:

NOAEL

Effect level:

1 000 mg/kg bw/day (nominal)

Sex:

male/female

Target system / organ toxicity

Critical effects observed:

not specified

Any other information on results incl. tables

Oral administration of the chemical to rats for a period of 28 consecutive days at dose levels up to 1000 mg/kg/day produced no treatment-related changes in the parameters measured.

Result: The test chemical was considered to have a “No Observed Adverse Effect Level” (NOAEL) of 1000 mg/kg/day.

Applicant's summary and conclusion

Conclusions:

The results of the study allowed an NOAEL of 1000 mg/kg/day (highest dose tested) to be clearly established.

Executive summary:

In a 28-day repeat dose oral toxicity study in rats there were statistically significant findings related to clinical chemistry, organ weight parameters, and macroscopic and microscopic changes in the kidney and lung. However, the findings were not dose-related and were

considered not to be treatment-related.